Repligen (NASDAQ: RGEN) reported Q1 EPS of $0.68, $0.26 better than the analyst estimate of $0.42. Revenue for the quarter came in at $142.8 million versus the consensus estimate of $117.01 million.

Tony J. Hunt, President and Chief Executive Officer said, “I am extremely proud of the way our team executed here in the first quarter. With unprecedented demand driven by strong COVID tailwinds, our whole team pivoted to deliver an impressive quarter with 88% growth and 69% organic. COVID revenue contribution ticked up to 25% of revenues in the first quarter and equally impressive was the performance of our non-COVID base business which was up 31% year-on-year. This is an endorsement of the differentiation we have in the marketplace with our technologies and the focus and execution of our global team. With accelerating orders, new product launches, planned new capacity and impressive growth across all four franchises, we are confident about the full year outlook for the Company and are updating our financial guidance to reflect our expectations for operating margin expansion and for organic revenue growth in the range of 42%-49%.”

GUIDANCE:

Repligen sees FY2021 revenue of $565-590 million, versus the consensus of $513.4 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.